SeqLL to Present at the H.C. Wainwright 24th Annual Global Conference

health news

BILLERICA, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) — SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services for collaborative partnerships, today announced that Daniel Jones, CEO of SeqLL will present a corporate overview and be available for virtual 1×1 meetings at the upcoming H.C. Wainwright 24th Annual Global Conference taking place from September 12-14, 2022.

The presentation will be available on demand beginning at 7:00 am ET on Monday, September 12th. To view the presentation or request a 1×1 meeting, click HERE to register and attend the event.

About SeqLL Inc.
SeqLL Inc. (“SeqLL”) is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple “omics” fields. The Company leverages its expertise with its True Single Molecule Sequencing (“tSMS®”) platform to empower scientists and researchers with improved genetic tools to better understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with today’s precision medicine. In sum, our experienced team works with our collaborators to develop innovative solutions tailored to the needs of each specific project.

Contacts:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel: +1 (617) 430-7577
Email: arr@lifesciadvisors.com